She had been to couples therapy for eight months. The sessions were good. The communication got better. The intimacy did not.
Her therapist was thoughtful, skilled, and never once suggested she get a hormone panel.
Nobody had. Not the GP, not the gynaecologist, not the therapist. And when she finally asked about it herself, she was told her estrogen looked "fine for her age."
Nobody had checked her testosterone. Nobody had checked her DHEA. Nobody had mentioned cortisol's role in suppressing free testosterone through a protein called sex hormone-binding globulin.
She was 46. She had been managing a physiological event as if it were a relational one for the better part of a year.
This is the conversation I hear most often, and the one most women are least likely to admit they need to have. There is still something about sexual desire that makes women edit themselves before the sentence is finished. They say "things have changed between us" or "I just don't feel like myself" and hope someone reads between the lines.
I built EmpressHealth.ai because those spaces between the lines are exactly where women fall through the clinical system.
So let's say it plainly. A lot has changed in your body's ability to generate sexual desire. It is not psychological first. It is physiological first. And the mechanism behind it is specific enough that if you understand it, you will never again accept "that's just part of this stage" as an answer.
Declining sexual desire in women in perimenopause is not a relationship problem wearing a medical costume.
It is a measurable hormonal event driven by the simultaneous decline of four separate chemical signals, each of which plays a distinct role in arousal, genital blood flow, and the brain's reward system.
Treating the relationship when the body is what needs treatment is a failure of clinical clarity. Not a personal failure. A systemic one.
Four hormones are changing at once, and all four matter
Sexual desire in women is regulated by a cluster of hormones that most clinicians discuss one at a time, if at all. Estradiol, the primary form of estrogen the ovaries produce, maintains genital blood flow, lubrication, and the sensitivity of nerve endings in the tissue that responds to arousal. As estradiol falls, physical responsiveness decreases before desire does. The body becomes less able to respond even when the mind is willing.
An eight-year cohort study following 226 women through the full menopause transition (Dennerstein et al.) found that estradiol levels were significantly correlated with both sexual responsiveness and desire throughout the transition. Testosterone, despite being the hormone most associated with libido in public discussion, was less consistently predictive on its own. The relationship between the two hormones matters as much as the level of either individually.
Testosterone in women is produced in small amounts by the ovaries and adrenal glands. It contributes to sexual desire by supporting the brain's dopamine reward circuits, the nerve sensitivity of genital tissue, and overall physical energy and motivation. By the time a woman reaches menopause, testosterone levels have typically reached approximately 50% of their peak levels. The fall is gradual and begins as early as the mid-30s. Many women describe the change not as a sudden loss of desire but as a slow withdrawal of something that used to arrive without effort.
Progesterone, when balanced with estrogen, supports mood stability, sleep depth, and the kind of physiological calm from which desire can actually emerge. When progesterone declines in perimenopause, many women describe a low-grade but persistent sense of anxiety or irritability that makes intimacy feel effortful in a way it never used to.
DHEA, which stands for dehydroepiandrosterone, is a hormone produced by the adrenal glands that the body converts into both testosterone and estrogen. It is also the hormone most likely to be left off a standard panel when a woman brings up low desire. Its decline through the perimenopause years removes a reserve of androgenic support that many women did not know they were relying on.
The cortisol and SHBG connection most clinicians skip
Here is the mechanism that is almost never explained. Chronic stress raises cortisol, the body's main stress hormone. Elevated cortisol directly suppresses the production of free testosterone by stimulating the liver to produce more sex hormone-binding globulin, written as SHBG.
SHBG is a protein that binds to testosterone in the blood, making it unavailable for the body to use. Think of SHBG as a taxi that picks up testosterone before it can reach its destination. The more SHBG the liver produces, the less free testosterone reaches the brain, the genital tissue, and the dopamine circuits where desire is generated.
This means that a woman under chronic stress, in perimenopause, with already-declining testosterone, is dealing with a triple suppression: less testosterone produced, more of it bound and unavailable, and a cortisol burden that amplifies every other hormonal deficit. A standard testosterone test that measures total testosterone will not show this. Only a test that measures free testosterone alongside SHBG will reveal the full picture.
The 2025 Guidelines from the Korean Society of Menopause are explicit on this point: when a woman reports decreased libido and is already on oral estrogen therapy, transdermal delivery is preferred precisely because oral estrogen raises SHBG and can reduce free testosterone further. Delivery method is not a minor detail. It changes what reaches the tissue.
What the clinical evidence actually supports
Low-dose transdermal testosterone has the strongest evidence base for low sexual desire in women in perimenopause and menopause. Multiple randomised controlled trials have shown improvements in sexual desire, satisfaction, arousal, and orgasmic response. The 2025 guidelines confirm this. What they also confirm is that treatment should not be based on testosterone blood levels alone, because desire in women is shaped by multiple overlapping systems and because the relationship between testosterone level and sexual experience is not linear.
Vaginal DHEA, approved in 2016 for genitourinary symptoms including pain during sex, converts inside cells into both androgens and estrogens. A clinical study confirmed that serum levels remained within the normal range following vaginal use, and the treatment is appropriate for many women including those with a history of breast cancer who cannot use systemic estrogen. Ask your clinician specifically about this option if vaginal dryness or discomfort is part of what has changed.
What does not address the mechanism: couples therapy alone, date nights alone, or reassurance that this is normal and will pass. None of those target the physiological drivers.
Why only 23% of women in perimenopause discuss this with a clinician
A published survey of 2,527 women found that 84% considered an active sex life important to them. Among women in perimenopause who reported reduced libido causing them distress, only 23% had discussed it with a health professional. Among women in menopause, the number rose to 35%.
That is not a data point about indifference. It is a data point about silence. About the women who edit themselves before the sentence is finished. About the appointments where this comes up and is resolved in two minutes with "that's common at this stage."
This symptom is not minor. It affects relationships, self-concept, physical wellbeing, and daily quality of life. It has a hormonal mechanism that is underinvestigated and undertreated. And it responds to targeted clinical intervention when that intervention is appropriately matched to the mechanism.
When she finally found a clinician who ran a full panel, including free testosterone and SHBG, the picture was clear. Her free testosterone was low. Her SHBG was high. Her cortisol pattern was elevated overnight. Three clinical targets. None of them had been identified in eight months of appointments.
She did not go back to couples therapy to discuss what had changed. Her relationship did not need more therapy. It needed her hormonal picture to be taken seriously.
That is a different kind of conversation. It starts with the body.
If your desire has changed and nobody has run a complete hormone panel including free testosterone, SHBG, DHEA, and a cortisol pattern, that is the conversation to open at your next appointment.
Not "is this normal?" but: "I want to understand the specific hormonal mechanism behind what has changed, and I want a full panel that includes free testosterone and SHBG."
That sentence gets a different answer.
Take the Assessment ๐ https://empresshealth.ai Join our waiting list ๐ hello@empresshealth.ai
Be you again. EmpressHealth.ai